Home / Publication / A Randomized, First-in-human, Healthy Volunteer Trial of Sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway

Publication

A Randomized, First-in-human, Healthy Volunteer Trial of Sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway

Author(s): Johann Bartko, Christian Schoergenhofer, Michael Schwameis, Christa Firbas, Martin Beliveau, Colin Chang, Jean-Francois Marier, Darrell Nix, James C. Gilbert, Sandip Panicker, Bernd Jilma

Year: May 8, 2018

Recommended for you

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Webinar

Pharmacokinetic Modeling of Neutralizing ADA Effects in Translational Development

Webinar

Extrapolating AUC to Infinity

Blog

Calculating AUC (Linear and Log-linear)

Blog

A Randomized, First-in-human, Healthy Volunteer Trial of Sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway

A Randomized, First-in-human, Healthy Volunteer Trial of Sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Pharmacokinetic Modeling of Neutralizing ADA Effects in Translational Development

Extrapolating AUC to Infinity

Calculating AUC (Linear and Log-linear)

Newsletter sign up

Quick links

Solutions

Contact